As a major stroke center, the Memorial Hermann Hospital-Texas Medical Center, Houston (MHH-TMC) has served as a leader in stroke research for some of the most important acute stroke studies in the world, including the NINDS tissue plasminogen activator (tPA) trial, which led to the approval of the clot-dissolving drug tPA in the treatment for acute stroke[33]. This evidence concerns the gene PLAT and Stroke.